Structural correlates of antibodies associated with acute reversal of amyloid β-related behavioral deficits in a mouse model of Alzheimer disease

Guriqbal S. Basi, Hadar Feinberg, Farshid Oshidari, John Anderson, Robin Barbour, Jeanne Baker, Thomas A. Comery, Linnea Diep, Davinder Gill, Kelly Johnson-Wood, Amita Goel, Katerina Grantcharova, Mike Lee, Jingzhi Li, Anthony Partridge, Irene Griswold-Prenner, Nicolas Piot, Don Walker, Angela Widom, Menelas N. PangalosPeter Seubert, J. Steven Jacobsen, Dale Schenk, William I. Weis

Research output: Contribution to journalArticlepeer-review

34 Scopus citations

Abstract

Immunotherapy targeting of amyloid β (Aβ) peptide in transgenic mouse models of Alzheimer disease (AD) has been widely demonstrated to resolve amyloid deposition as well as associated neuronal, glial, and inflammatory pathologies. These successes have provided the basis for ongoing clinical trials of immunotherapy for treatment of AD in humans. Acute as well as chronic Aβ-targeted immunotherapy has also been demonstrated to reverse Aβ-related behavioral deficits assessing memory in AD transgenic mouse models. We observe that three antibodies targeting the same linear epitope of Aβ, Aβ3-7, differ in their ability to reverse contextual fear deficits in Tg2576 mice in an acute testing paradigm. Reversal of contextual fear deficit by the antibodies does not correlate with in vitro recognition of Aβ in a consistent or correlative manner. To better define differences in antigen recognition at the atomic level, we determined crystal structures of Fab fragments in complex with Aβ. The conformation of the Aβ peptide recognized by all three antibodies was highly related and is also remarkably similar to that observed in independently reported Aβ:antibody crystal structures. Sequence and structural differences between the antibodies, particularly in CDR3 of the heavy chain variable region, are proposed to account for differing in vivo properties of the antibodies under study. These findings provide a structural basis for immunotherapeutic strategies targeting Aβ species postulated to underlie cognitive deficits in AD.

Original languageEnglish (US)
Pages (from-to)3417-3427
Number of pages11
JournalJournal of Biological Chemistry
Volume285
Issue number5
DOIs
StatePublished - Jan 29 2010

Fingerprint Dive into the research topics of 'Structural correlates of antibodies associated with acute reversal of amyloid β-related behavioral deficits in a mouse model of Alzheimer disease'. Together they form a unique fingerprint.

Cite this